The efficacy of adeno-associated virus (AAV)-mediated gene therapy for the inner ear is fundamentally constrained by the natural tropism of viral vectors, which often lack the precision and efficiency ...
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing partner JCR Pharmaceuticals to develop genomic medicines. Under the deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results